x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Global Oncology Academy

The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments. For more information about GOA, visit www.globaloncologyacademy.org.

science & medicine medicine

All Episodes

00:00:00

AML Care: Examining the Efficacy and Safety of a...

Global Oncology Academy ·

2025/03/14

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Anthony Stein, MD Could a novel triplet combination therapy offer a new path forward in acute myeloid leukemia (AML) treatment? A recent Phase 1B trial explored the potential of tagraxofusp, azacitidine, and venetoclax for AML patients. To discuss the findings on this triplet combination therapy, Dr. Charles Turck speaks with Dr. Anthony Stein, Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of

en

00:00:00

AML Care: Examining the Efficacy and Safety of a...

Global Oncology Academy ·

2025/03/14

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Anthony Stein, MD Could a novel triplet combination therapy offer a new path forward in acute myeloid leukemia (AML) treatment? A recent Phase 1B trial explored the potential of tagraxofusp, azacitidine, and venetoclax for AML patients. To discuss the findings on this triplet combination therapy, Dr. Charles Turck speaks with Dr. Anthony Stein, Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of

en

00:00:00

Collaborative Insights to Solve the Puzzle of Bladder...

Global Oncology Academy ·

2025/03/14

Host: Daniel P. Petrylak, MD Guest: Elizabeth R. Plimack, MD, MS, FASCO Guest: Evan Y. Yu, MD This online educational activity, derived from a live satellite symposium at ASCO GU 2025, explores innovative strategies for personalized care in bladder cancer. Participants will gain a deeper understanding of molecular targets and profiling methodologies, review cutting-edge clinical trial evidence, and examine the latest advances in therapy delivery. The program also focuses on

en

00:00:00

Chemotherapy Strategies for Metastatic PDAC

Global Oncology Academy ·

2025/01/13

Guest: Efrat Dotan, MD Guest: Shubham Pant, MD, MBBS Pancreatic ductal adenocarcinoma, otherwise known as PDAC, is a lethal disease which is usually diagnosed at an advanced stage and has an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases,

en

00:00:00

Diagnosis and Management of Metastatic PDAC

Global Oncology Academy ·

2025/01/13

Guest: Efrat Dotan, MD Guest: Shubham Pant, MD, MBBS Pancreatic ductal adenocarcinoma, otherwise known as PDAC, is a lethal disease which is usually diagnosed at an advanced stage and has an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases,

en

00:00:00

Predictive Models for CAR T-Cell Therapy:...

Global Oncology Academy ·

2025/01/08

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Matasar, MD When treating relapsed or refractory large B-cell lymphoma (R/R LBCL) with CAR T-cell therapy, the risk of adverse events is a key consideration. Models such as PhasED-Seq and CAR-HEMATOTOX can help clinicians assess the patient’s risk and personalize care plans regarding treatment selection and location, prophylactic regimen, and early intervention strategies. Tune in to hear Dr. Charles Turck and Dr. Matthew

en

00:00:00

Predictive Models for CAR T-Cell Therapy:...

Global Oncology Academy ·

2025/01/08

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Matasar, MD When treating relapsed or refractory large B-cell lymphoma (R/R LBCL) with CAR T-cell therapy, the risk of adverse events is a key consideration. Models such as PhasED-Seq and CAR-HEMATOTOX can help clinicians assess the patient’s risk and personalize care plans regarding treatment selection and location, prophylactic regimen, and early intervention strategies. Tune in to hear Dr. Charles Turck and Dr. Matthew

en

00:00:00

Mastering CAR-T Cell Therapy in R/R Large B-Cell...

Global Oncology Academy ·

2025/01/07

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sairah Ahmed, MD Guest: Caron A. Jacobson, MD The side effects associated with CAR T-cell therapy are very different than those seen with other cancer therapies and include cytokine-release syndrome (CRS) and neurotoxicity. It’s important to know how to recognize the signs of these adverse events and treat patients with relapsed or refractory large B-cell lymphoma early to avoid drastic quality-of-life impacts. To help improve

en

00:00:00

Preventing Adverse Events in CAR T-Cell Therapy: The...

Global Oncology Academy ·

2025/01/02

Guest: Tara Graff, DO, MS Host: Charles Turck, PharmD, BCPS, BCCCP While CAR T-cell therapy is an effective option for patients with certain blood cancers like lymphoma and myeloma, it’s associated with two common adverse events: cytokine release syndrome and neurotoxicity. Given those risks, safety protocols have evolved over time to include strategies like aggressive hydration, prophylactic use of corticosteroids, early intervention with tocilizumab, and multidisciplinary care

en

00:00:00

NSCLC Care: Predicting Response to Dato-DXd with a...

Global Oncology Academy ·

2024/12/13

Host: Jacob Sands, MD Guest: Marina Garassino, MD Datopotamab deruxtecan (Dato-DXd) is a second-line antibody drug conjugate that could lead to improved progression-free survival in patients with advanced or metastatic non-small cell lung cancer. Given these potential benefits, it’s important to identify biomarkers that may predict a patient’s response to Dato-DXd, which was the focus of recent research presented at the 2024 World Conference on Lung Cancer. Here with Dr. Jacob

en

00:00:00

Poster Pearl: Treating ER+/HER2- mBC with Elacestrant...

Global Oncology Academy ·

2024/11/27

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Hope S. Rugo, MD, FASCO While endocrine therapy (ET) and CDK4/6 inhibitors are the standard for treating ER+/HER2- metastatic breast cancer, patients can become resistant to ET. To overcome these resistance mechanisms, the ELEVATE study examines whether combining elacestrant with ET could help address this unmet need. Here to share the preliminary findings from ELEVATE with Dr. Charles Turck is lead study investigator Dr. Hope Rugo

en

00:00:00

Improving Adherence to CRC Screening: A Primary Care...

Global Oncology Academy ·

2024/10/31

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sara Enslin, PA Current colorectal cancer (CRC) screening rates are low, putting patients at risk of developing more advanced disease and even increased mortality. Primary care physicians play a critical role in reversing this troubling trend, which is why Dr. Charles Turck speaks with Ms. Sarah Enslin about strategies for improving adherence to CRC screening in the primary care setting. Ms. Enslin is a physician assistant at the

en

00:00:00

The Promise of MCED Testing: Easing the Burden of...

Global Oncology Academy ·

2024/08/06

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Christopher Chambers, MD Guest: Adam H. Buchanan, MS, MPH Since multi-cancer early detection (MCED) testing is a new technology, there’s been some discussion in the field about the impact it may have on patients, especially in terms of potential psychological harm like anxiety related to positive test results and false positive test results. Joining Dr. Charles Turck to discuss findings from a recent qualitative survey and the

en

00:00:00

Uncovering New Biomarkers for RCC: A Review of...

Global Oncology Academy ·

2024/07/30

Host: Jody Takemoto, PhD Guest: David Braun Identifying biomarkers for renal cell carcinoma (RCC) is critical since they can help direct our therapeutic approach, which is why several techniques that may be able to uncover new biomarkers are currently being investigated. Joining Dr. Jody Takemoto to review those techniques and their potential impacts on RCC care is Dr. David Braun, Assistant Professor of Medicine and a member of the Center of Molecular and Cellular Oncology at Yale

en

00:00:00

The Potential Impact of RCC Molecular Subtypes on...

Global Oncology Academy ·

2024/07/29

Host: Jody Takemoto, PhD Guest: David Braun, MD, PhD A recent study investigated whether renal cell carcinoma (RCC) molecular subtypes have any impact on treatment outcomes. Here to share the surprising findings and their implications is Dr. David Braun, Assistant Professor of Medicine and a member of the Center of Molecular and Cellular Oncology at Yale Cancer Center.

en

00:00:00

Delivering Guideline-Based Hepatocellular Carcinoma...

Global Oncology Academy ·

2024/07/23

Host: Jody Takemoto, PhD Guest: Robert Wong, MD Since the guidelines for diagnosing and treating hepatocellular carcinoma are often lengthy and complicated, it can be difficult for clinicians to stay up to date on the current recommendations and implement them in clinical practice. That’s why a team with the HCC Steering Committee of the Chronic Liver Disease Foundation developed a web-based, interactive tool that incorporates current guideline recommendations to help clinicians

en

00:00:00

Emerging Frontiers: CAR T-Cell Therapy for Solid...

Global Oncology Academy ·

2024/07/16

Host: Matt Birnholz, MD Guest: Saad Kenderian M.B, Ch.B CAR T-cell therapy has been revolutionary in the treatment of blood cancers like chronic lymphocytic leukemia and multiple myeloma, and according to recent research, this therapeutic approach may also help patients with thyroid cancer. However, there are several challenges associated with applying this technology to target solid tumors in thyroid cancer, like tumor heterogeneity and resistance. Joining Dr. Matt Birnholz to

en

00:00:00

Dual Challenges: Managing Hepatocellular Carcinoma...

Global Oncology Academy ·

2024/07/09

Host: Jody Takemoto, PhD Guest: Robert Wong, MD Hepatitis B is one of the leading causes of liver cancer globally, underscoring the importance of screening, diagnosing, and treating patients appropriately. However, there are several considerations to keep in mind when caring for patients with hepatocellular carcinoma with hepatitis B co-infection, which is why Dr. Jody Takemoto speaks with Dr. Robert Wong about those factors and essential management strategies. Dr. Wong is a

en

00:00:00

Uncovering Barriers to HCC Surveillance in Patients...

Global Oncology Academy ·

2024/07/03

Host: Jody Takemoto, PhD Guest: Robert Wong, MD A recent study explored clinician-level gaps and barriers to hepatocellular carcinoma surveillance in patients with cirrhosis and found that there is a lot of work to be done to help improve knowledge about cirrhosis, the recommended cancer screening guidelines, and how to implement those recommendations. Joining Dr. Jody Takemoto to discuss these findings and how we can address the uncovered challenges is Dr. Robert Wong, Clinical

en

00:00:00

Treating mCRPC with Lutetium-177 and Radium-223:...

Global Oncology Academy ·

2024/03/13

Guest: Alan Bryce, MD Lutetium-177and radium-223 have both been shown to significantly improve survival in patients with metastatic castration-resistant prostate cancer, but how do these treatment options compare? Find out with Dr. Alan Bryce, who presented a session on this exact topic at the 2024 ASCO Genitourinary Cancers Symposium.

en

83 results

Similar Podcasts

科学史评话最新专辑

科学史评话

Hablando con Científicos - Cienciaes.com

cienciaes.com

天方烨谈

基因频道

The Permaculture Podcast

Scott Mann

汪诘：科学有故事（主打）

科学有故事